TRVN Trevena Inc.

-0.04  -3%
Previous Close 1.31
Open 1.29
Price To Book 2.54
Market Cap 117289120
Shares 92,353,638
Volume 623,003
Short Ratio
Av. Daily Volume 1,457,486

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2018. Additional QT interval data required - trial to commence June, 2019.
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 2b endpoints not met - May 2016
Acute heart failure
Phase 1 trial complete.
Acute migraine

Latest News

  1. Edited Transcript of TRVN earnings conference call or presentation 13-May-19 12:00pm GMT
  2. Trevena: 1Q Earnings Snapshot
  3. Trevena Reports First Quarter 2019 Results
  4. Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
  5. Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
  6. Introducing Trevena (NASDAQ:TRVN), The Stock That Tanked 83%
  7. AMAG Pharmaceuticals Appoints New Members to Board of Directors
  8. Trevena (TRVN) Gains As Market Dips: What You Should Know
  9. Edited Transcript of TRVN earnings conference call or presentation 13-Mar-19 12:00pm GMT
  10. Will Trevena Continue to Surge Higher?
  11. Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
  12. Watch These Four Healthcare Stocks Set The Pace On Tuesday
  13. Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
  14. Trevena says it has 'clear path' to resubmit application for experimental pain medicine
  15. PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
  16. Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
  17. Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
  18. Trevena Reports Fourth Quarter and Full Year 2018 Results
  19. Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain